Methods of Modulating Angiogenesis

Description: The invention is based on the finding that the delta isoform of Protein Kinase C can modulate pathways leading to angiogenesis or cell growth. Specifically, PKC-delta was found to regulate endothelial cell differentiation into tubes. Agonists of PKC-delta can be used to promote tube formation to reduce permeability, while PKC-delta antagaonists can be used to prevent or reduce tube formation, thereby inhibiting angiogenesis. The inventions can be practiced using known antagonists or agonists of these kinase isoforms. Clinical & Commercial Utility: The invention therefore provides novel potential strategies for the modulation of cell growth or angiogenesis, using agonists or antagonists to PKC-delta. Joslin’s issued patent claims cover screening methods to identify drug candidates for inhibition of angiogenesis.
Joslin Diabetes Center is the owner of U.S. Patent Number 7,410,756 claiming this invention.

Type of Offer: Licensing

Next Patent »
« More Medical Patents

Share on      

CrowdSell Your Patent